Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3 + T-regulatory Cell Function and Promotes Antitumor Immunity

EBioMedicine

Volumn 13, Issue , 2016, Pages 99-112

  Wang, Liqing ^a   Kumar, Suresh ^b   Dahiya, Satinder ^a   Wang, Feng ^b   Wu, Jian ^b   Newick, Kheng ^c   Han, Rongxiang ^a   Samanta, Arabinda ^a   Beier, Ulf H ^a   Akimova, Tatiana ^a   Bhatti, Tricia R ^a   Nicholson, Benjamin ^b   Kodrasov, Mathew P ^b   Agarwal, Saket ^b   Sterner, David E ^b   Gu, Wei ^d   Weinstock, Joseph ^b   Butt, Tauseef R ^b   Albelda, Steven M ^c   Hancock, Wayne W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Progenra Inc   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NONE   (United States)

Author keywords

Anti tumor immunity; Deubiquitination; Immuno oncology; T regulatory cells

Indexed keywords

DEUBIQUITINASE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; HISTONE ACETYLTRANSFERASE; KAT5 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN; USP7 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL FUNCTION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; HEART TRANSPLANTATION; HOMEOSTASIS; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNITY; DISEASE MODEL; GENE EXPRESSION; GENETICS; IMMUNITY; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; AUTOIMMUNITY; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HISTONE ACETYLTRANSFERASES; IMMUNITY; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANS-ACTIVATORS; TUMOR BURDEN; UBIQUITIN-SPECIFIC PROTEASES;

EID: 85006107031     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.10.018     Document Type: Article

References (71)

1. American_Cancer_Society, Cancer Facts and Figures. 2015, In American Cancer Society 2015.
2. Antony, P.A., Piccirillo, C.A., Akpinarli, A., Finkelstein, S.E., Speiss, P.J., Surman, D.R., Palmer, D.C., Chan, C.C., Klebanoff, C.A., Overwijk, W.W., et al. CD8 + T cell immunity against a tumor/self-antigen is augmented by CD4 + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174 (2005), 2591–2601.
3. Attia, P., Maker, A.V., Haworth, L.R., Rogers-Freezer, L., Rosenberg, S.A., Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28 (2005), 582–592.
4. Battke, F., Symons, S., Nieselt, K., Mayday–integrative analytics for expression data. BMC Biotechnol., 11, 2010, 121.
5. Beyer, M., Schultze, J.L., Regulatory T cells in cancer. Blood 108 (2006), 804–811.
6. Boudreaux, D.A., Maiti, T.K., Davies, C.W., Das, C., Ubiquitin vinyl methyl ester binding orients the misaligned active site of the ubiquitin hydrolase UCHL1 into productive conformation. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 9117–9122.
7. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
8. Chauhan, D., Tian, Z., Nicholson, B., Kumar, K.G., Zhou, B., Carrasco, R., McDermott, J.L., Leach, C.A., Fulcinniti, M., Kodrasov, M.P., et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22 (2012), 345–358.
9. Colombo, M., Vallese, S., Peretto, I., Jacq, X., Rain, J.C., Colland, F., Guedat, P., Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem 5 (2010), 552–558.
10. Cummins, J.M., Rago, C., Kohli, M., Kinzler, K.W., Lengauer, C., Vogelstein, B., Tumour suppression: disruption of HAUSP gene stabilizes. Nature, 428, 2004, 53 (1 p following 486).
11. Curiel, T.J., Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117 (2007), 1167–1174.
12. Dar, A., Shibata, E., Dutta, A., Deubiquitination of Tip60 by USP7 determines the activity of the p53-dependent apoptotic pathway. Mol. Cell. Biol. 33 (2013), 3309–3320.
13. De Ceuninck, L., Wauman, J., Masschaele, D., Peelman, F., Tavernier, J., Reciprocal cross-regulation between RNF41 and USP8 controls cytokine receptor sorting and processing. J. Cell Sci. 126 (2013), 3770–3781.
14. Dougan, M., Dranoff, G., Immune therapy for cancer. Annu. Rev. Immunol. 27 (2009), 83–117.
15. Dranoff, G., CTLA-4 blockade: unveiling immune regulation. J. Clin. Oncol. 23 (2005), 662–664.
16. Du, T., Nagai, Y., Xiao, Y., Greene, M.I., Zhang, H., Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers. Exp. Mol. Pathol. 95 (2013), 38–45.
17. Dyck, L., Wilk, M.M., Raverdeau, M., Misiak, A., Boon, L., Mills, K.H., Anti-PD-1 inhibits Foxp3 + Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model. Cancer Immunol. Immunother., 2016, 10.1007/s00262-016-1906-6 (in press).
18. Faesen, A.C., Dirac, A.M., Shanmugham, A., Ovaa, H., Perrakis, A., Sixma, T.K., Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase. Mol. Cell 44 (2011), 147–159.
19. Fietta, A.M., Morosini, M., Passadore, I., Cascina, A., Draghi, P., Dore, R., Rossi, S., Pozzi, E., Meloni, F., Systemic inflammatory response and downmodulation of peripheral CD25 + Foxp3 + T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer. Hum. Immunol. 70 (2009), 477–486.
20. Fontenot, J.D., Rasmussen, J.P., Gavin, M.A., Rudensky, A.Y., A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6 (2005), 1142–1151.
21. Fu, W., Ergun, A., Lu, T., Hill, J.A., Haxhinasto, S., Fassett, M.S., Gazit, R., Adoro, S., Glimcher, L., Chan, S., et al. A multiply redundant genetic switch ‘locks in’ the transcriptional signature of regulatory T cells. Nat. Immunol. 13 (2012), 972–980.
22. Gallimore, A., Godkin, A., Regulatory T cells and tumour immunity - observations in mice and men. Immunology 123 (2008), 157–163.
23. Gallimore, A.M., Simon, A.K., Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 27 (2008), 5886–5893.
24. Gao, Y., Koppen, A., Rakhshandehroo, M., Tasdelen, I., van de Graaf, S.F., van Loosdregt, J., van Beekum, O., Hamers, N., van Leenen, D., Berkers, C.R., et al. Early adipogenesis is regulated through USP7-mediated deubiquitination of the histone acetyltransferase TIP60. Nat. Commun., 4, 2013, 2656.
25. Gavin, M.A., Rasmussen, J.P., Fontenot, J.D., Vasta, V., Manganiello, V.C., Beavo, J.A., Rudensky, A.Y., Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445 (2007), 771–775.
26. Ha, T.Y., The role of regulatory T cells in cancer. Immune Netw 9 (2009), 209–235.
27. Haas, A.R., Sun, J., Vachani, A., Wallace, A.F., Silverberg, M., Kapoor, V., Albelda, S.M., Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin. Cancer Res. 12 (2006), 214–222.
28. Hanahan, D., Weinberg, R.A., The hallmarks of cancer. Cell 100 (2000), 57–70.
29. Hancock, W.W., Buelow, R., Sayegh, M.H., Turka, L.A., Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat. Med. 4 (1998), 1392–1396.
30. Huang da, W., Sherman, B.T., Lempicki, R.A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4 (2009), 44–57.
31. Jackaman, C., Bundell, C.S., Kinnear, B.F., Smith, A.M., Filion, P., van Hagen, D., Robinson, B.W., Nelson, D.J., IL-2 intratumoral immunotherapy enhances CD8 + T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J. Immunol. 171 (2003), 5051–5063.
32. Jing, X., Infante, J., Nachtman, R.G., Jurecic, R., E3 ligase FLRF (Rnf41) regulates differentiation of hematopoietic progenitors by governing steady-state levels of cytokine and retinoic acid receptors. Exp. Hematol. 36 (2008), 1110–1120.
33. Ke, X., Wang, J., Li, L., Chen, I.H., Wang, H., Yang, X.F., Roles of CD4 + CD25(high) FOXP3 + Tregs in lymphomas and tumors are complex. Front. Biosci. 13 (2008), 3986–4001.
34. Knutson, K.L., Dang, Y., Lu, H., Lukas, J., Almand, B., Gad, E., Azeke, E., Disis, M.L., IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. 177 (2006), 84–91.
35. Kon, N., Zhong, J., Kobayashi, Y., Li, M., Szabolcs, M., Ludwig, T., Canoll, P.D., Gu, W., Roles of HAUSP-mediated p53 regulation in central nervous system development. Cell Death Differ. 18 (2011), 1366–1375.
36. Lee, P.P., Fitzpatrick, D.R., Beard, C., Jessup, H.K., Lehar, S., Makar, K.W., Perez-Melgosa, M., Sweetser, M.T., Schlissel, M.S., Nguyen, S., et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15 (2001), 763–774.
37. Lee, I., Wang, L., Wells, A.D., Dorf, M.E., Ozkaynak, E., Hancock, W.W., Recruitment of Foxp3 + T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J. Exp. Med. 201 (2005), 1037–1044.
38. Li, M., Brooks, C.L., Kon, N., Gu, W., A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 13 (2004), 879–886.
39. Li, B., Samanta, A., Song, X., Iacono, K.T., Bembas, K., Tao, R., Basu, S., Riley, J.L., Hancock, W.W., Shen, Y., et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 4571–4576.
40. Lin, K.Y., Guarnieri, F.G., Staveley-O'Carroll, K.F., Levitsky, H.I., August, J.T., Pardoll, D.M., Wu, T.C., Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56 (1996), 21–26.
41. Liu, Y., Wang, L., Han, R., Beier, U.H., Hancock, W.W., Two lysines in the forkhead domain of foxp3 are key to T regulatory cell function. PLoS One, 7, 2012, e29035.
42. Liu, Y., Wang, L., Predina, J., Han, R., Beier, U.H., Wang, L.C., Kapoor, V., Bhatti, T.R., Akimova, T., Singhal, S., et al. Inhibition of p300 impairs Foxp3 + T regulatory cell function and promotes antitumor immunity. Nat. Med. 19 (2013), 1173–1177.
43. Liu, Y., Wang, L., Han, R., Beier, U.H., Akimova, T., Bhatti, T., Xiao, H., Cole, P.A., Brindle, P.K., Hancock, W.W., Two histone/protein acetyltransferases, CBP and p300, are indispensable for Foxp3 + T-regulatory cell development and function. Mol. Cell. Biol. 34 (2014), 3993–4007.
44. Nicholson, B., Suresh Kumar, K.G., The multifaceted roles of USP7: new therapeutic opportunities. Cell Biochem. Biophys. 60 (2011), 61–68.
45. Nishikawa, H., Sakaguchi, S., Regulatory T cells in tumor immunity. Int. J. Cancer 127 (2010), 759–767.
46. O'Callaghan, D.S., Rexhepaj, E., Gately, K., Coate, L., Delaney, D., O'Donnell, D.M., Kay, E., O'Connell, F., Gallagher, W.M., O'Byrne, K.J., Tumour islet Foxp3 + T-cell infiltration predicts poor outcome in nonsmall cell lung cancer. Eur Respir J 46 (2015), 1762–1772.
47. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
48. Petersen, R.P., Campa, M.J., Sperlazza, J., Conlon, D., Joshi, M.B., Harpole, D.H. Jr., Patz, E.F. Jr., Tumor infiltrating Foxp3 + regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107 (2006), 2866–2872.
49. Powell, D.J. Jr., Felipe-Silva, A., Merino, M.J., Ahmadzadeh, M., Allen, T., Levy, C., White, D.E., Mavroukakis, S., Kreitman, R.J., Rosenberg, S.A., et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J. Immunol. 179 (2007), 4919–4928.
50. Qin, F.X., Dynamic behavior and function of Foxp3 + regulatory T cells in tumor bearing host. Cell. Mol. Immunol. 6 (2009), 3–13.
51. Reyes-Turcu, F.E., Ventii, K.H., Wilkinson, K.D., Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem. 78 (2009), 363–397.
52. Roth, S.Y., Denu, J.M., Allis, C.D., Histone acetyltransferases. Annu. Rev. Biochem. 70 (2001), 81–120.
53. Rubtsov, Y.P., Rasmussen, J.P., Chi, E.Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W.R. Jr., et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28 (2008), 546–558.
54. Rubtsov, Y.P., Niec, R.E., Josefowicz, S., Li, L., Darce, J., Mathis, D., Benoist, C., Rudensky, A.Y., Stability of the regulatory T cell lineage in vivo. Science 329 (2010), 1667–1671.
55. Rudra, D., deRoos, P., Chaudhry, A., Niec, R.E., Arvey, A., Samstein, R.M., Leslie, C., Shaffer, S.A., Goodlett, D.R., Rudensky, A.Y., Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat. Immunol. 13 (2012), 1010–1019.
56. Sadlon, T.J., Wilkinson, B.G., Pederson, S., Brown, C.Y., Bresatz, S., Gargett, T., Melville, E.L., Peng, K., D'Andrea, R.J., Glonek, G.G., et al. Genome-wide identification of human FOXP3 target genes in natural regulatory T cells. J. Immunol. 185 (2010), 1071–1081.
57. Sharma, P., Wagner, K., Wolchok, J.D., Allison, J.P., Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 11 (2011), 805–812.
58. Song, X., Li, B., Xiao, Y., Chen, C., Wang, Q., Liu, Y., Berezov, A., Xu, C., Gao, Y., Li, Z., et al. Structural and biological features of FOXP3 dimerization relevant to regulatory T cell function. Cell Rep. 1 (2012), 665–675.
59. Tao, R., de Zoeten, E.F., Ozkaynak, E., Chen, C., Wang, L., Porrett, P.M., Li, B., Turka, L.A., Olson, E.N., Greene, M.I., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13 (2007), 1299–1307.
60. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
61. van Loosdregt, J., Vercoulen, Y., Guichelaar, T., Gent, Y.Y., Beekman, J.M., van Beekum, O., Brenkman, A.B., Hijnen, D.J., Mutis, T., Kalkhoven, E., et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 115 (2010), 965–974.
62. van Loosdregt, J., Fleskens, V., Fu, J., Brenkman, A.B., Bekker, C.P., Pals, C.E., Meerding, J., Berkers, C.R., Barbi, J., Grone, A., et al. Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 39 (2013), 259–271.
63. Wang, L., Liu, Y., Han, R., Beier, U.H., Bhatti, T.R., Akimova, T., Greene, M.I., Hiebert, S.W., Hancock, W.W., FOXP3 + regulatory T cell development and function require histone/protein deacetylase 3. J. Clin. Invest. 125 (2015), 1111–1123.
64. Weinstock, J., Wu, J., Cao, P., Kingsbury, W.D., McDermott, J.L., Kodrasov, M.P., McKelvey, D.M., Suresh Kumar, K.G., Goldenberg, S.J., Mattern, M.R., et al. Selective dual inhibitors of the cancer-related Deubiquitylating proteases USP7 and USP47. ACS Med. Chem. Lett. 3 (2012), 789–792.
65. Woo, E.Y., Chu, C.S., Goletz, T.J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S.C., Kaiser, L.R., June, C.H., Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61 (2001), 4766–4772.
66. Wu, X., Yen, L., Irwin, L., Sweeney, C., Carraway, K.L. 3rd, Stabilization of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8. Mol. Cell. Biol. 24 (2004), 7748–7757.
67. Xiao, Y., Nagai, Y., Deng, G., Ohtani, T., Zhu, Z., Zhou, Z., Zhang, H., Ji, M.Q., Lough, J.W., Samanta, A., et al. Dynamic interactions between TIP60 and p300 regulate FOXP3 function through a structural switch defined by a single lysine on TIP60. Cell Rep. 7 (2014), 1471–1480.
68. Yang, H.Y., Barbi, J., Wu, C.Y., Zheng, Y., Vignali, P.D., Wu, X., Tao, J.H., Park, B.V., Bandara, S., Novack, L., et al. MicroRNA-17 modulates regulatory T cell function by targeting Co-regulators of the Foxp3 transcription factor. Immunity 45 (2016), 83–93.
69. Zheng, Y., Josefowicz, S., Chaudhry, A., Peng, X.P., Forbush, K., Rudensky, A.Y., Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463 (2010), 808–812.
70. Zitvogel, L., Tesniere, A., Kroemer, G., Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6 (2006), 715–727.
71. Zitvogel, L., Apetoh, L., Ghiringhelli, F., Andre, F., Tesniere, A., Kroemer, G., The anticancer immune response: indispensable for therapeutic success?. J. Clin. Invest. 118 (2008), 1991–2001.